Indonesia Completes Personalized COVID-19 Vaccine Study

California-based AIVITA Biomedical, Inc.,  announced the completion of a Phase 1 clinical study in Indonesia of its personalized vaccine candidate, AV-COVID-19, for the SARS-CoV-2 virus. The 27-participant Phase 1 study showed the treatment was well-tolerated, with no serious adverse events, and that treated individuals produced antibodies.

The clinical program is being conducted by PT AIVITA Biomedika Indonesia, a joint venture established between AIVITA and local partners with support from the government of Indonesia. AV-COVID-19 is being manufactured locally by AIVITA.

AIVITA is in discussions with regulatory authorities for a Phase 2 study in Indonesia, as well as a clinical investigation of AV-COVID-19 in the USA in early 2021.

“We continue to see an unprecedented global need for preventative vaccines that can be rapidly scaled and adapted to provide protection against all COVID-19 viral variants,” said Hans Keirstead, Ph.D., chief executive officer of AIVITA, in a press release.

“Our personalized vaccine can be created locally to support regional economic stimulation, using a kit that can be produced rapidly at scale. In addition, our materials can be adapted to quickly create new vaccines against mutations of the virus. With this decentralized model, we can conduct studies in Indonesia and prepare for worldwide distribution.”

AIVITA Biomedical, Inc. is a personalized vaccine company evaluating vaccines for the prevention of COVID-19 infection and treatment of cancer.